More countries are developing strategies to combat antimicrobial resistance (AMR), but inadequate diagnostic testing, limited funding and gaps in treatment continue to expose patients to drug-resistant infections, the World Health Organization (WHO) has warned.
New WHO data show that 173 countries had developed national action plans to tackle AMR in 2026, more than double the 79 countries reported in 2017. However, only 22 per cent of countries have secured the necessary funding and fully implemented their plans.
The findings come ahead of World AMR Awareness Week, observed from November 18 to 24, and highlight the gap between government commitments and the services patients need to prevent and treat resistant infections.
AMR occurs when bacteria, viruses, fungi and parasites no longer respond effectively to medicines, making infections harder to treat and increasing the risks associated with routine medical procedures, childbirth, surgery and cancer treatment.
In 2023, approximately one in six laboratory-confirmed bacterial infections globally was resistant to antibiotics, underscoring the growing challenge facing health systems.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said national action plans were important in protecting the effectiveness of medicines, but warned that commitments without implementation would not adequately protect patients.
He called on governments to invest in infection prevention, disease surveillance, access to essential antimicrobials and quality diagnostic services.
A major concern identified in the latest Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS) is the limited capacity of countries to identify resistant infections.
Only 36 per cent of countries reported having national reference laboratories equipped to test selected bacteria and fungi. This remains significantly below the global target of 80 per cent of countries having comprehensive bacterial and fungal resistance testing capacity by 2030.
Without reliable diagnostic services, patients risk receiving antibiotics that may not work against their infections or taking medicines when they are not necessary. Inadequate testing also makes it harder for health authorities to identify outbreaks and understand patterns of drug resistance.
The report further shows that only 63 per cent of countries have guidelines for the appropriate use of antimicrobials, while just over half have surveillance systems to monitor antibiotic consumption and track resistance.
To address these challenges, WHO has introduced two practical tools under its Antimicrobial Resistance Diagnostic Initiative. The resources include a prioritised catalogue of diagnostic tests and standard operating procedures to strengthen laboratory capacity in identifying bacterial and fungal infections and testing antimicrobial susceptibility.
The findings are based on the 2026 TrACSS assessment, completed by 183 countries, representing 94 per cent of WHO Member States.
Established in 2016, the survey is a global mechanism for tracking national progress in implementing AMR action plans. It is jointly developed by the Food and Agriculture Organization, United Nations Environment Programme, WHO and World Organisation for Animal Health.
This year’s World AMR Awareness Week will be held under the theme, “One Health, one action: Prevent AMR now”, emphasising the connection between human, animal, plant and environmental health.
The campaign calls for coordinated action by governments, healthcare workers, farmers, veterinarians, environmental experts and communities to prevent the emergence and spread of drug-resistant infections.


